Geert-Jan Mulder MD
Managing Partner
The company is focused on the research and development of novel therapeutic approaches to address unmet needs in diseases related to complement dysregulation.
The ground-breaking research conducted by the founders has led to valuable new insights regarding the role of complement in both ocular and systemic diseases.
The company is focused on the research and development of novel therapeutic approaches to address unmet needs in diseases related to complement dysregulation. In developing such therapies, multiple platforms are being pursued including AAV gene therapies as well as protein-based approaches. Alongside our therapeutic strategy, the company has developed a highly novel mass spectrometry platform (the Complement Precision Medicine platform) enabling the simultaneous measurement of >30 complement proteins from a systemic blood sample.
Industry
Biotech
Status
Current
Location
Germany
The potential transformative impact of Complement Therapeutics lead asset (CTx001) as a treatment for geographic atrophy (GA) secondary to age related macular degeneration (AMD) is significant. The emerging profile of CTx001 indicates it has the potential to be a highly differentiated therapeutic for this devastating condition that currently affects more than 5 million people globally. The support and guidance from Forbion has been outstanding throughout this journey.Rafiq Hasan
CEO of Complement Therapeutics
€72m
Series A financing
Forbion team
Dmitrij Hristodorov PhD
General Partner